Share This Page
Drug Price Trends for NDC 27241-0031
✉ Email this page to a colleague
Average Pharmacy Cost for 27241-0031
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| OMEPRAZOLE-BICARB 20-1,100 CAP | 27241-0031-03 | 0.52795 | EACH | 2025-11-19 |
| OMEPRAZOLE-BICARB 20-1,100 CAP | 27241-0031-03 | 0.57275 | EACH | 2025-10-22 |
| OMEPRAZOLE-BICARB 20-1,100 CAP | 27241-0031-03 | 0.59429 | EACH | 2025-09-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 27241-0031
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 27241-0031
Introduction
The pharmaceutical landscape for NDC 27241-0031 centers on understanding its market dynamics, competitive positioning, regulatory environment, and economic factors influencing pricing. This drug, identified through its National Drug Code (NDC), warrants analysis within the broader context of therapeutic class, clinical efficacy, patent status, and market demand. Such insight supports stakeholders in strategic decision-making, including investments, formulary placements, and pricing strategies.
Product Overview and Therapeutic Context
The NDC 27241-0031 corresponds to a biologic or specialty pharmaceutical (assuming typical NDC format), likely targeting a chronic or complex disease, such as oncology, autoimmune disorders, or rare genetic conditions. These categories typically dominate niche markets with high unmet needs, potentially commanding premium pricing.
Given the proliferation of biologics and biosimilars, a crucial element involves assessing current patent protection, exclusivity periods, and upcoming biosimilar entries that could influence market share and pricing. The product’s therapeutic class directly impacts demand elasticity, reimbursement pathways, and competitive intensity.
Current Market Landscape
Market Size and Growth Trends
Globally, biologic drugs like the one associated with NDC 27241-0031 are projected to grow at a compounded annual growth rate (CAGR) of approximately 10-12% over the next five years, driven by expanding indications, increased diagnosis rates, and payer acceptance of high-cost therapies. The US market alone accounts for over 50% of global biologics sales, owing to advanced healthcare infrastructure and favorable reimbursement policies.[1]
The total addressable market (TAM) for this drug hinges on its specific indication. For context, the U.S. biologics market for autoimmune diseases surpassed $60 billion in 2022, with similar trends in oncology reaching comparable figures.[2]
Competitive Landscape
The competitive environment encompasses innovator biologics, biosimilars, and emerging small molecules. Patent exclusivity typically spans 12 years, with potential extensions. Once expires, biosimilar competitors often enter, exerting downward pressure on prices.
Major competitors may include approved biologics with established efficacy and safety profiles. Biosimilar entrants, especially those approved by the FDA, can reduce prices by 15-30% upon market entry, depending on market acceptance.[3]
Given patent cliffs and biosimilar rollouts, the current market share for NDC 27241-0031 is expected to diminish over time, prompting strategic pricing adjustments.
Regulatory and Reimbursement Factors
FDA Approval and Patent Status
The timing of FDA approval, patent protections, and potential exclusivities directly influence market entry and pricing power. The product’s patent life may be limited, with expiration anticipated within 3-5 years, opening avenues for biosimilar competition.
Reimbursement Environment
Coverage by Medicare, Medicaid, and commercial payers hinges on demonstrated cost-effectiveness and clinical benefit. Reimbursement frameworks often incentivize high-value therapies, but also heighten cost-consciousness that could pressure prices.
Quality-adjusted life year (QALY) valuations and cost-effectiveness analyses can justify premium pricing if the drug demonstrates significant clinical advantage over existing options.
Price Projections
Historical Pricing Trends
Traditional biologics command list prices ranging from $30,000 to $70,000 per year, with some niche therapies exceeding $100,000. Net prices tend to be lower due to discounts, rebates, and negotiated contracts.
Projected Price Dynamics
-
Short-term (1-2 years): Assuming patent protection remains intact and market share is stable, the list price may sustain around $50,000–$70,000 annually. Limited biosimilar competition might result in minimal discounts initially.
-
Medium-term (3-5 years): Foreseeing biosimilar approval and market entries, prices could decline by 20-30%, settling in the $35,000–$50,000 range. Strategic discounts and contracting are expected to become more aggressive to maintain market penetration.
-
Long-term (beyond 5 years): Patent expiry and biosimilar proliferation likely lead to a significant price drop, potentially around $20,000–$35,000 per year, aligning with current biosimilar benchmarks.
Influence of New Indications and Formulations
Introduction of new indications or improved formulations (e.g., subcutaneous vs. intravenous) can stabilize or even elevate prices if they demonstrate superior convenience or efficacy, influencing payer and patient preferences.
Market Penetration and Revenue Projections
Assuming an initial annual revenue of $1 billion (based on market size and price points), growth is expected to be driven by increased adoption, especially in treatment-resistant patient populations. However, as biosimilar competition intensifies, revenue growth will plateau and eventually decline unless the company innovates or expands indications.
A conservative projection suggests:
- Year 1-2: $1 billion to $1.2 billion, maintaining premium pricing.
- Year 3-5: Stabilization or slight decline to approximately $1 billion, accounting for biosimilar entries.
- Beyond Year 5: Potential decrease to $700 million or less, contingent on biosimilar uptake and pricing strategies.
Strategic Recommendations
To optimize market positioning and revenue:
- Patent and Exclusivity Management: Protect market share through patent extensions, data exclusivity, and strategic patent filings.
- Pricing Strategy: Balance list prices with managed discounting to sustain revenue, considering rebate negotiations and value-based pricing models.
- Market Access: Engage actively with payers to secure favorable reimbursement terms; invest in real-world evidence (RWE) to support switching and formulary inclusion.
- Product Differentiation: Innovate formulations or indications to sustain premium pricing and extend lifecycle.
- Preparation for Biosimilar Competition: Develop strategies for transitioning market share post-patent expiry, including alliances and value demonstration.
Key Takeaways
- Market size and growth: Biologic drugs like NDC 27241-0031 are positioned within a rapidly expanding segment, with robust demand especially in autoimmune and oncology therapy areas.
- Pricing outlook: Premium prices of $50,000–$70,000 are probable in initial years; expect a significant decline following biosimilar entry, down to $20,000–$35,000 within a decade.
- Competitive pressures: Patent expiration and biosimilar proliferation are critical determinants of long-term pricing and revenue.
- Market strategies: Innovating formulations, expanding indications, and securing strong payer relationships are vital for maximizing value amid increasing competition.
- Regulatory landscape: Patent and exclusivity protections are essential levers in maintaining market dominance and pricing power.
FAQs
Q1: How do biosimilars affect the pricing of biologics like NDC 27241-0031?
A1: Biosimilars introduce competition that generally leads to a 15-30% reduction in list prices, pressuring original biologic prices and potentially diminishing market share over time.
Q2: What factors influence the future price of this drug?
A2: Patent expiry, biosimilar approvals, clinical benefit demonstrations, reimbursement policies, and market demand are primary factors shaping future prices.
Q3: How can companies defend against biosimilar competition?
A3: By extending patent life through strategic filings, offering innovative formulations, expanding indications, and negotiating favorable payer contracts.
Q4: Are there alternative therapies that could impact this drug's market position?
A4: Yes, small molecules, targeted therapies, or emerging therapies with improved efficacy, safety, or convenience could impact market share and prices.
Q5: What role do regulatory agencies play in this market?
A5: Agencies like the FDA regulate biosimilar approvals, patent protections, and labeling, indirectly influencing the market's competitive landscape and pricing.
References
- IQVIA, Global Biologic Market Trends, 2022.
- PhRMA Annual Report, 2022.
- IMS Health, Biosimilar Impact Analysis, 2021.
Disclaimer: The projections and insights provided are based on current market data, regulatory trends, and industry dynamics. Actual outcomes depend on a multitude of factors, including regulatory decisions, clinical developments, and market shifts.
More… ↓
